Ballicules.com

Prasugrel

EFFIENT

What it isIrreversible P2Y12 antagonist; acute coronary syndrome managed with PCI.

Why this onePlatelet inhibition is stronger and more consistent than with clopidogrel and does not depend on CYP2C19 phenotype.

What limits itPrior stroke or TIA is an absolute contraindication; advanced age, low body weight, and surgery magnify bleeding risk.

FDA-approved for

FDA label

BOXED WARNING Bleeding risk (significant, sometimes fatal). Do not use with active bleeding or history of TIA/stroke. Generally not recommended ≥75 yr. Do not start if urgent CABG likely; d/c ≥7 days before surgery
FDA dosingPopulationStartTargetMax
Acute coronary syndrome managed with PCI (reduce thrombotic CV events)Adults60 mg loading dose10 mg QD10 mg QD

Renal Undefined

Hepatic Undefined

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy No human data; weigh bleeding risk to fetus

Lactation Undefined

⚠ BOXED WARNING

Cost, est. cash$4–$300/month

Generic entry2017

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger3 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryB

Defining liabilityGI or intracranial bleeding, especially with anticoagulants, NSAIDs or serotonergic antidepressants.

Mechanism of action: Prasugrel ballicule

Prasugrel ballicule: receptor binding, kinetics and half-life diagram

Open Prasugrel in the interactive console ↗

Memory aids: mascots and interaction avatars

Prasugrel EFFIENT mascot mnemonic cartoon
“Defiant Pressure grill”
Blue platelet grilled

Open Prasugrel in the interactive console ↗